Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p0164135/European-Markets-for-Womens-Health-Devices-2009-(15-Countries).html">http://www.reportlinker.com/p0164135/European-Markets-for-Womens-Health-Devices-2009-(15-Countries).html [More]

Angiotech Pharmaceuticals, Inc. today announced its financial results for the third quarter ended September 30, 2009. [More]

BioSphere Medical, Inc. – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer. [More]

Research and Markets (http://www.researchandmarkets.com/research/d494fb/european_markets_f) has announced the addition of the "European Markets for Women's Health Devices 2009 (15 Countries)" report to their offering. [More]

BioSphere Medical, Inc. – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – reports the publication of a study in the October 2009 issue of the Journal of Vascular Interventional Radiology in which the authors conclude that uterine artery embolization (UAE) compares favorably to laparoscopic occlusion of uterine arteries in the treatment of uterine leiomyomas (fibroids) in cases where hysterectomy or myomectomy are not options. [More]

The Magnetic Resonance Center of the University Children's Hospital Zurich has achieved a world first break through in MR-guided, non-invasive neurosurgery. Ten patients have been successfully treated by means of transcranial high-intensity focused ultrasound. This fully non-invasive procedure opens new horizons for neurosurgery and the treatment of different neurological brain disorders. [More]

Sonohysterography (SHG), a simple ultrasound technique commonly used to evaluate the uterine cavity, improves the diagnostic capability of transvaginal ultrasound in detecting adenomyosis (a common benign condition of the uterus that causes dysmenorrhea, abnormal vaginal bleeding and pelvic pain), according to a study performed at the Thomas Jefferson University Hospital in Philadelphia, PA. [More]

The treatment of uterine fibroids with 3T MR-guided focused ultrasound (MRgFUS) is safe, non-invasive and effective, according to a recent study conducted by researchers at Weill Cornell Medical College in New York, NY. [More]

Uterine fibroid embolization (UFE), a minimally invasive interventional radiology treatment for uterine fibroids, provides significant relief of symptoms for women whose focused ultrasound (FUS) treatment failed, according to a study released during the Society of Interventional Radiology's 33rd Annual Scientific Meeting in Washington, D.C. Primary care physicians and gynecologists can feel confident in informing patients that a failed FUS treatment does not require subsequent gynecological surgery. [More]

A study presented at the Society of Interventional Radiology's 33rd Annual Scientific Meeting shows of 105 patients in the Atlanta metro area, only 18 percent of the women who saw a private practice gynecologist were told about uterine fibroid embolization (UFE), a minimally invasive treatment for uterine fibroids provided by interventional radiologists. [More]

A noninvasive, outpatient treatment for noncancerous uterine tumors provides sustained relief from symptoms, according to a new Mayo Clinic led collaborative study. [More]

A systematic review of the research concerning treatment options for uterine fibroids, which affect most American women over 50, reveals surprisingly little evidence to help compare standard treatment recommendations, according to a report by researchers at the RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center, which is sponsored by the Agency for Healthcare Research and Quality. [More]

Israel-based Elbit Medical Imaging on Monday said that FDA has approved software that aims to reduce treatment time for the uterine fibroid device ExAblate 2000, the AP/Forbes reports. [More]

The first study of uterine fibroid embolization to treat post-menopausal women shows that the non-surgical treatment was technically successful in 100 percent of patients, and improved bulk-related symptoms in 92 percent of the women. [More]

In the first long term study of patients receiving uterine fibroid embolization (UFE) for the relief of symptoms from fibroid tumors 73% report continued relief five years later. [More]